Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LAE005 / Laekna Therap
NCT05390710: PhI to Solid Tumors and PhII to Locally Advanced or mTNBC	Completed	1	21	RoW	LAE005 + Afuresertib + Nab-Paclitaxel	Laekna Limited	Solid Tumor, TNBC - Triple-Negative Breast Cancer	12/23	12/23
NCT02936102: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.	Terminated	1	154	Europe, Canada, Japan, US, RoW	FAZ053, PDR001	Novartis Pharmaceuticals	Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma	11/24	11/24